Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04281277
Other study ID # 49RC19_0236
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 6, 2020
Est. completion date March 15, 2026

Study information

Verified date October 2022
Source University Hospital, Angers
Contact Nicolas FAGE, Resident
Phone 0241355865
Email fage.nicolas@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study evaluates if improvement of renal resistive index when mean arterial pressure increase (at 65 mmHg to 85 mmHg) in early phase of septic shock is predictive of better renal survival.


Description:

Learned societes (survival sepsis campaign and ESICM) are currently recommending a mean arterial pressure (MAP) target at 65 mmHg in septic shoc with a potential increase to 85 mmHg in patients with medical history of arterial hypertension. A high renal resistive index on the first day of septic shock was associated with acute renal failure more frequently on the 5th day. A decrease in the renal resistance index was also objectified during the increase in MAP. The main objective of this trial is to study the relationship between the improvement of the resistance index during a test of increase in average blood pressure during septic shock and the improvement of renal function In this interventional monocenter trial, we will measure the renal resistive index after stabilization of the MAP at 65 mmHg for two hours, then after 2 hours of stabilization at 85 mmHg. This part allows us to define the patients "responding" to the renal resistive index (improvement of the resitive renal index when the MAP increases). Then, patients will be randomized into two groups : - first group with a MAP target at 65 mmHg - second group with a MAP target at 85 mmHg. There will be a stratification on the responder character to the renal resistance index. Finally, we will assess renal function on the 7th day (with the assessment of serum creatinine and the change of stage of the KDIGO classification)


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date March 15, 2026
Est. primary completion date January 15, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - adult patients (= 18 ans) - Admitted to the intensive care unit of Angers with - arterial hypotension requiring the etablishment of catecholamines - In a context of proven or suspected sepsis, whaterver the cause of this infection. - norepinephrine dose ? 0.1µg/kg/min - After 2 hours of stabilization at 65 mmHg of mean arterial pressure Exclusion Criteria: - Pre-existing chronic renal failure (glomerular filtration rate < 60 mL/min with MDRD) - Solitary kidney (anatomical or functional) - History of united or bilateral stenosis of the renal arteries - decision to stop or limit treatment - patient with an emergency indication of renal replacement therapy (severe hyperkalemia, severe metabolical acidosis with pH <7.15, acute pulmonary edema due to fluid overload resulting in severe hypoxemia, serum urea concentration > 40 mmol/l and oliguria/anuria > 72 h.) - pregnant, lactating or parturient woman - patient deprived of liberty by judicial or administrative decision - patient with psychiatric compulsory care - patient subject to legal protection measures

Study Design


Related Conditions & MeSH terms


Intervention

Device:
increase of mean arterial pressure at 80-85 mmHg.
increase of mean arterial pressure at 80-85 mmHg (with catecholamines or volemic expansion).
increase of mean arterial pressure at 65-70 mmHg.
increase of mean arterial pressure at 65-70 mmHg (with catecholamines or volemic expansion).

Locations

Country Name City State
France CHU Angers. Médecine Intensive Réanimation et médecine hyperbare Angers

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Angers

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary changes of KDIGO stage modification of the KDIGO classification stage (estimated based on serum creatinine and diuresis) between the group with low target of mean arterial pressure ( 65-70 mmHg) and high target MAP (80-85 mmHg) Inclusion and day 7
Secondary Renal resistive index We will assess the evolution of the renal resistive index during an increase in the target of MAP in the early phase of septic shock . We will assess the evolution of renal resistive index according to the comorbidities, as a function of time in septic shock, according to the hemodynamic data, according to quantity of filling solution administered and catecholamine doses Inclusion, and 2 hours of mean arterial pressure stabilized at 85 mmHg and every day (day 1 to day 7)
Secondary Collection of all adverse event Difference in sides effects between target at 65-70 mmHg of MAP and 80-85 mmHg. Day 1 to day 7
Secondary amount of fluids (unit = L or L/day) Inclusion, day 1 to day 7
Secondary catecholamines free days day 1 to day 7
Secondary extra renal replacement free days Difference in need of renal replacement therapy between the group of 80-85mmHg and the groupe 65-70 mmHg, depending on the responder character Daily to day 1 to day 7, at day 28 and day 90
Secondary Number of day with supportive care in intensive care unit (renal replacement therapy, mechanical ventilation, extracorporeal membrane oxygenation) Quantification of the number of days with supportive care (catecholamine,renal replacement therapy, mechanical ventilation, extracorporeal membrane oxygenation) Collection daily between Day 1 and Day 7, at Day 28.
Secondary Number of day in intensive care unit Quantification of the number of days hospitalized in intensive care unit Collection at Day 28 and Day 90
Secondary Number of day in hospital Quantification of the number of days hospitalized. Collection at Day 28 and Day 90
Secondary hemodynamic data collected by swan ganz or PICCO catheter Inclusion and at 2 hours, daily between Day 1 and Day 7
Secondary quantity of nephrotoxic drugs Inclusion and daily between Day 1 and Day 7.
Secondary serum creatinine (unit = µmol/L) Inclusion and daily between Day 1 and Day 7
Secondary Diuresis (unit = mL per day) Daily between day 1 and day 7
Secondary Survival at day 28 patient status (live or dead) at day 28
Secondary Survival at day 90 patient status (live or dead) at day 90
See also
  Status Clinical Trial Phase
Recruiting NCT03649633 - Vitamin C, Steroids, and Thiamine, and Cerebral Autoregulation and Functional Outcome in Septic Shock Phase 1/Phase 2
Terminated NCT04117568 - The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
Completed NCT04227652 - Control of Fever in Septic Patients N/A
Completed NCT05629780 - Temporal Changes of Lactate in CLASSIC Patients N/A
Recruiting NCT04796636 - High-dose Intravenous Vitamin C in Patients With Septic Shock Phase 1
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Recruiting NCT04005001 - Machine Learning Sepsis Alert Notification Using Clinical Data Phase 2
Recruiting NCT05217836 - Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
Recruiting NCT05066256 - LV Diastolic Function vs IVC Diameter Variation as Predictor of Fluid Responsiveness in Shock N/A
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3
Not yet recruiting NCT04516395 - Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae N/A
Recruiting NCT02899143 - Short-course Antimicrobial Therapy in Sepsis Phase 2
Recruiting NCT02580240 - Administration of Hydrocortisone for the Treatment of Septic Shock N/A
Recruiting NCT02676427 - Fluid Responsiveness in Septic Shock Evaluated by Caval Ultrasound Doppler Examination
Recruiting NCT02565251 - Volemic Resuscitation in Sepsis and Septic Shock N/A
Terminated NCT02335723 - ASSET - a Double-Blind, Randomized Placebo-Controlled Clinical Investigation With Alteco® LPS Adsorber N/A
Not yet recruiting NCT02547467 - TOADS Study: TO Assess Death From Septic Shock. N/A
Completed NCT02638545 - Hemodynamic Effects of Dexmedetomidine in Septic Shock Phase 3
Completed NCT02204852 - Co-administration of Iloprost and Eptifibatide in Septic Shock Patients Phase 2
Completed NCT02079402 - Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care Phase 4